A groundbreaking discovery has been made, shedding light on a critical process during cell division. Researchers from Osaka University and MIT have unveiled a new molecular mechanism that ensures chromosomes align correctly during mitosis. This mechanism involves two key motor proteins, KIF18A and CENP-E, which work in harmony to maintain proper chromosome congression. The study's findings not only provide valuable insights into the fundamentals of cell division but also open up exciting possibilities for cancer treatment.
Accurate chromosome segregation is vital for healthy cell division. When this process fails, it can lead to chromosomal instability, a hallmark of cancer. The kinetochore, a protein complex on chromosomes, plays a crucial role in coordinating this process. However, the intricate interplay of various proteins has made it challenging to pinpoint the exact mechanisms.
The research team employed a unique approach, using a cell line with a partially defective kinetochore. By screening for genetic weaknesses, they discovered that disrupting the KIF18A gene led to cell death. Further investigations revealed that these cells also had reduced levels of CENP-E, another motor protein. This finding suggests that KIF18A and CENP-E collaborate to drive early-stage chromosome alignment, with CENP-C acting as a key regulator.
In normal cells, if one protein's function is compromised, the other can often compensate. However, when both proteins are impaired, chromosome alignment fails, resulting in cell death. This discovery has significant implications for cancer treatment. The research team found that cancer cells with naturally low CENP-E levels are highly sensitive to KIF18A inhibition. Combined inhibition of both proteins effectively induces cell death, offering a promising therapeutic strategy.
The study suggests that cancer cells with low CENP-E levels become particularly vulnerable to drugs targeting KIF18A. Measuring CENP-E levels could help identify cancers that respond well to KIF18A-blocking drugs. Additionally, combining drugs that affect these two proteins may enhance the effectiveness of cancer treatments.
"We have not only unraveled the intricate mechanisms of chromosome segregation but also demonstrated their potential in selectively killing cancer cells," said Tatsuo Fukagawa, the study's senior author and professor at Osaka University. "This highlights the importance of grounding targeted therapies in basic research."
The study's findings offer a new perspective on chromosome congression during mitosis and provide a promising avenue for cancer research and treatment. Further investigations are needed to fully understand the implications of these findings and develop targeted therapies.
